Global /Sweden /Healthcare /Biotechnology /BIOSGN

Biosergen AB (publ)

BIOSGN

• STO: BIOSGN • Delayed

10.10SEK 0%

1.07 USD

As of 8 June 2026, Biosergen AB (publ) has a market cap of $2.53M USD, ranking #46626 globally and #799 in Sweden. It ranks #4125 in the Healthcare sector, and #811 in the Biotechnology industry.

Global Rank

46626

Country Rank

799

Sector Rank

4125

Industry Rank

811

Key Stats

Market Cap

$2.53MUSD

23.72M SEK

Enterprise Value

$881.36KUSD

8.35M SEK

Net Income (TTM)

-$4.35MUSD

-40.82M SEK

PB Ratio

2.9

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Biotechnology

CEO

Tine Olesen open_in_new

Employees

Founded

2004

Website

biosergen.net open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	4.1%	-72%	-76%	-79%	-74%	-66%	-91%	-99%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	BIOSGN ISIN: SE0026821852 Shares Out.: Shares Outstanding: 2.348M¹ Shares Float: 1.356M² TV: TradingView: OMXSTO: BIOSGN SA: Stock Analysis: STO: BIOSGN YF: Yahoo Finance: BIOSGN.ST GF: Google Finance: STO: BIOSGN BA: Barron's: BIOSGN MS: Morningstar: XSTO: BIOSGN	10.10 SEK	TV: TradingView: OMXSTO: BIOSGN SA: Stock Analysis: STO: BIOSGN YF: Yahoo Finance: BIOSGN.ST GF: Google Finance: STO: BIOSGN BA: Barron's: BIOSGN MS: Morningstar: XSTO: BIOSGN

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Biosergen AB (publ)

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Similar Companies

Industry: Biotechnology (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Vimian Group AB (publ) STO: VIMIAN	$1.59B 14.9B SEK 63K%	43.7	Sweden
BioInvent International AB (publ) STO: BINV	$151.29M 1.42B SEK 6K%	-	Sweden
BICO Group AB (publ) STO: BICO	$141.71M 1.33B SEK 6K%	-	Sweden
Cinclus Pharma Holding AB (publ) STO: CINPHA	$60.38M 565.9M SEK 2K%	-	Sweden
Intervacc AB (publ) STO: IVACC	$41.82M 391.94M SEK 2K%	-	Sweden
Bio-Works Technologies AB (publ) NGM: BIOWKS	$33.1M 310.2M SEK 1K%	-	Sweden

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 7M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 6M%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 2M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 2M%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 2M%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 2M%	37.2	Switzerland

chevron_leftBack